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Abstract 
Objective: With the survival rate of acute lymphoblastic leukemia (ALL) surpassing 90 
percent within this decade, new research is emerging in the field of late effects.  A review of 
the research investigating the relationship of treatment regimens for ALL to specific late effect 
deficits, underlying mechanisms, and possible remediation is warranted to support continued 
studies.    
Methods: The clinical literature was briefly surveyed to describe the occurrence and to-
pography of late effects, specifically neurocognitive deficits.  Additionally, the preclinical lit-
erature was reviewed to uncover potential underlying mechanisms of these deficits.  The 
advantages of using rodent models to answer these questions are outlined, as is an assessment 
of the limited number of rodent models of childhood cancer treatment.  
Results:   The literature supports that childhood survivors of ALL exhibit academic difficul-
ties and are more likely to be placed in a special education program.  Behavioral evidence has 
highlighted impairments in the areas of attention, working memory, and processing speed, 
leading to a decrease in full scale IQ.  Neurophysiological and preclinical evidence for these 
deficits has implicated white matter abnormalities and acquired brain damage resulting from 
specific chemotherapeutic agents commonly used during treatment.   
Conclusions: The exact role of chemotherapeutic agents in learning deficits remains mostly 
unknown.  Recommendations for an improved rodent model of learning deficits in childhood 
cancer survivors are proposed, along with suggestions for future directions in this area of 
research, in hopes that forthcoming treatment regimens will reduce or eliminate these types 
of impairments. 
Key  words:  childhood  cancer,  cognitive  late  effects,  acute  lymphoblastic  leukemia,  preclinical 
models, chemotherapy 
Late Effects of Childhood Cancer 
Out of 10 million cancer survivors alive in the 
United States today, at least 270,000 were diagnosed 
when they were under the age of 21 [1].  With the 
advancement of cancer treatment over the past few 
decades, new interest focuses on ―late effects,‖ chronic 
and progressive conditions associated with successful 
completion of cancer therapy, which are now preva-
lent among long-term cancer survivors.  Such effects 
Ivyspring  
International Publisher   Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
293 
usually  present  three  or  more  years  post-diagnosis, 
with only one in three survivors remaining free of any 
long-term problems [2,3].  Late effects among child-
hood cancer survivors are so pervasive that the Chil-
dren‘s Oncology Group has issued a recommendation 
for regular evaluation to monitor development after 
treatment, a guideline that is often difficult to follow 
due  to  time-consuming  and  expensive  assessments 
[4].  
 Included among a plethora of chronic medical 
conditions are cognitive late effects, presumably re-
sulting from chemotherapy administered to the cen-
tral  nervous  system  (CNS)  during  a  time  of  rapid 
brain  development  [3,5].    For  instance,  childhood 
cancer survivors, compared to siblings, are 10 times 
more likely to have severe cognitive deficits, and are 
significantly less likely to complete high school or to 
complete higher education after graduation [3,6].  In 
adulthood, frequency of impairment in areas of task 
efficiency,  memory,  and  emotional  regulation  is  50 
percent higher among survivors of childhood cancer 
compared to siblings [7].    
 Among childhood cancer survivors, acute lym-
phoblastic  leukemia  (ALL)  is  the  most  common  di-
agnosis  [8].    Due  to  the  advancement  of  treatment 
regimens, it is now expected that over 90 percent of 
children  diagnosed  with  ALL  will  enter  into 
long-term  remission,  giving  it  the  highest  survival 
rate for pediatric cancers [9].  Extensive reviews of the 
clinical  literature  surrounding  cognitive  late  effects 
associated with ALL treatment exist [10,11], whereas 
evaluation of cognitive late effects in preclinical mod-
els of young rodents is lacking. Therefore, the objec-
tive of the current review is to highlight the benefits of 
using  preclinical  models  to  complement  clinical  re-
search in this area.        
Acute Lymphoblastic Leukemia (ALL) 
Leukemias  represent  about  one-third  of  child-
hood cancers, with ALL accounting for 75 percent of 
pediatric leukemia cases, making it the most common 
form of cancer in children and adolescents [12]. Out of 
4,000 cases diagnosed annually in the United States, 
two-thirds are in these age groups [9].  ALL, a malig-
nant disorder of lymphoid cells, results when a sur-
plus of stem cells develop into lymphocytes, a type of 
white  blood  cell  also  referred  to  as  leukemic  cells.  
These cells are not able to fight infection and leave less 
room for healthy cells and platelets [9].  Additionally, 
since these cells are found in bone marrow they are 
transported by the circulatory system to nearly every 
organ system, including the CNS.  Despite possible 
environmental, genetic, and viral influences, the exact 
cause of ALL in most cases remains unknown [13].  
While ALL is less prevalent in adults, the mortality 
rate among  this  population  is  much  higher  than  in 
adolescents and children.  
Treatment  for  the  majority  of  ALL  subtypes 
consists  of  three  phases:  induction,  intensification 
(consolidation)  therapy,  and  continuation  (mainte-
nance) treatment.  Although two-thirds of childhood 
cases are curable with only 12 months of treatment, 
the vast majority of patients undergo therapy for two 
years  or  more  [9].    Across  medical  institutions, 
chemotherapeutic  agents  used  vary  in  type  and 
amount, with the most common being methotrexate 
(MTX),  cytosine  arabinoside  (cytarabine),  anthracy-
clines  (such  as  doxorubicin),  asparaginase,  mercap-
topurine,  vincristine,  and  corticosteroids,  presented 
alone or in combination [9].  Cranial irradiation, or 
cranial radiation therapy (CRT), once the most com-
mon form of CNS prophylaxis, has largely been re-
placed by intrathecal (IT) and systemic chemotherapy.  
This change has been made in an effort to eliminate 
radiation-specific  damage  to  the  CNS  [14].    Recent 
regimens have tested whether CRT can be eliminated 
completely from standard treatment.  To date, this has 
been  successful,  although  alterations  in  long-term 
outcome are just beginning to unfold [15].    
Academic and Learning Deficits 
 Childhood ALL and its treatments are associat-
ed with poor academic outcome, with age at diagnosis 
being the most important education-related risk fac-
tor.  One study of infant leukemia, defined as children 
diagnosed at age 12 months or younger, found that 50 
percent  exhibited  learning  deficits  more  than  five 
years after diagnosis, and the risk increased for each 
month younger in age at the time of treatment [16].  
Survivors of ALL have a greater likelihood of being 
placed  in  a  special  education  program,  earn  lower 
grades in school on average, and reach a lower edu-
cational level than their siblings [17,18].  While ALL 
treatment during childhood is related to overall poor 
academic performance, clear learning deficits may not 
arise  until  four  or  five  years  after  the  initiation  of 
treatment [19].   Interestingly, poor academic perfor-
mance  is  not  correlated  with  frequent  absenteeism 
from school, as may seem to be a plausible explana-
tion due to intensive treatments [20]. 
Given  the  fact  that  past  treatment  for  ALL 
commonly included CRT, the majority of studies on 
this topic have included radiation as part of partici-
pant treatment, but rarely without simultaneous use 
of chemotherapy [2].  General measures of intellectual 
functioning were used in these studies, such as the 
Wechsler Intelligence Scales [21].  Reports of scores 
declining for at least seven years following treatment Journal of Cancer 2011, 2 
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including cranial irradiation have been noted [22].  It 
has been suggested that childhood cancer survivors 
display a decreased rate of learning new information 
and acquiring new skills, leading to a decline in IQ 
score [2,23].   
Comparisons  between  CNS  prophylaxes  in-
volving  CRT  or  IT  therapy  have  yielded  mixed  re-
sults, with several studies finding no significant dif-
ference  between  treatment  groups.    For  example, 
while  a  12-point  difference  in  mean  IQ  score  was 
found between ALL patients and controls, including 
sibling and solid tumor control groups, this result was 
irrespective of CNS prophylaxis type [24].  The ob-
servation that the radiation and non-radiation treat-
ment groups both demonstrated deficits may indicate 
synergistic effects between MTX and cytarabine, with 
the latter increasing the neurotoxic effects of the for-
mer, creating a  result similar  to CRT.  Along  these 
lines, no significant influence of treatment group was 
found between children who received IT MTX in ad-
dition to systemic (IV) MTX, a lower dose of CRT, or a 
higher  dose  of  CRT,  although  22  to  30  percent  of 
children displayed a clinically significant decline in IQ 
[23].    Other  chemotherapeutic  agents  were  used  in 
later phases of treatment, however, which may have 
played a role in the findings.  Alternatively, systemic 
MTX may potentiate the neurotoxic effects of IT MTX 
by  affecting  the  brain  via  indirect  pathways  [25].  
High  doses  of  MTX  administered  IV  may  reduce 
vascularization of the brain, particularly hippocampal 
blood vessel density [26].    
Loss of intellectual functioning, characterized by 
IQ level, is considered to be secondary, resulting from 
a range of core deficits.  Among these are deficits in 
attention,  working  memory,  and  processing  speed 
[13].    Most  studies  examining  neurocognitive  im-
pairments in ALL survivors have focused on deficits 
in attention, since severe attentional problems occur 
in  approximately  one-quarter  of  survivors,  though 
findings  vary  depending on  the specific  subtype of 
attention examined [27].  Deficits in the targeting, re-
calling,  and  manipulating  of  information  to  guide 
goal-directed behavior have been noted up to seven 
years post-treatment [28,29].  In addition, ALL survi-
vors  performed  poorly  on  a  visual  attention  task, 
which required the child to shift attention between the 
local and global level of stimuli [30].  Children diag-
nosed younger than 54 months of age exhibit difficul-
ties in both fundamental and complex attention skills.  
Children diagnosed older than 54 months of age have 
difficulty with more complex skills only, such as ac-
tive mental switching and sustained attention [31].  It 
should be noted, however, that deficits in more com-
plex skills likely arise from reduced fluency in sim-
pler, component skills, even if these types of deficits 
did not reach significance.  In addition to age at di-
agnosis,  treatment  intensity  also  may  impact  atten-
tional  functioning,  with  children  given  intensified 
treatments  displaying  more  extensive  and  wide-
spread difficulties [32].  
 From a developmental standpoint, disruption in 
basic skills may not become apparent until difficulties 
with  higher-level  abilities  surface  years  later,  when 
emergence  of  complex  repertoires  from  component 
skills do not occur in normal progression.  One pro-
posed theory of ALL survivors‘ decrease in IQ level 
links the cognitive skills of processing speed, working 
memory, and fluid intelligence, with processing speed 
playing  a  significant  role  in  the  development  of 
working  memory  [33].    In  turn,  working  memory 
underlies the development of higher-level reasoning 
and fluid intelligence.  Evidence for impaired working 
memory and slowed information processing has been 
found  for  ALL  survivors  given  chemotherapy-only 
treatment, especially when multiple pieces of infor-
mation are involved [34,35,36,37]. 
Although  the  substitution  of  IT  chemotherapy 
for cranial irradiation has possibly reduced the sever-
ity  of  the  impairments  outlined  above  [38,39],  evi-
dence  of  long-term  neurocognitive  deficits  in  ALL 
survivors still exists [10,11,36].  One such study ex-
amined  the  learning  and  academic  functioning  of 
children who received chemotherapy alone as treat-
ment for ALL.  As compared to newly diagnosed pa-
tients, children who had completed a 3-year chemo-
therapy-only  regimen showed  greater cognitive im-
pairments and were more likely to have diagnosable 
learning disabilities as well, despite the fact that no 
learning  difficulties  had  been  identified  for  these 
children prior to their ALL diagnosis [19].  In a com-
parison of IT MTX and triple IT therapy (including 
MTX, cytarabine, and hydrocortisone), no significant 
difference in level of cognitive impairment was found 
between groups, although the MTX group displayed a 
slightly slower processing speed [40].  Recent studies 
suggest  that  up  to  40  percent  of  childhood  cancer 
survivors  given  chemotherapy-only  treatment  may 
experience neurocognitive deficits years later [4].   
Much of the clinical findings from longitudinal 
studies  on  the  impact  of  chemotherapy-only  treat-
ment  for  ALL  have  been  inconsistent,  possibly  be-
cause  of  differences  among  methodological  ap-
proaches and medical protocols. There are multiple 
methodological  challenges  in  longitudinal  cognitive 
assessment,  such  as  selection  of  appropriate  neu-
rocognitive domains and control groups, differences 
in criteria for impairment, and repeated testing [41].  It 
is  suggested  that  the  percentage  of  ALL  survivors Journal of Cancer 2011, 2 
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experiencing  neurocognitive  deficits  may  rise  to  70 
percent depending on the specific type of cognitive 
domain assessed, particularly in the area of working 
memory [42].  In addition, ALL treatment protocols 
often differ in a multitude of ways, leaving the ques-
tion of which agents and doses affect neurocognitive 
outcome largely unknown [11,12].  Given that treat-
ment  is  comprised  of  multiple  phases,  each  with  a 
unique  combination  of  drugs,  it  has  been  demon-
strated that even a single agent substitution within the 
complex protocol alters whether or not cognitive late 
effects appear [43].   
Neurophysiological Evidence 
 Neurophysiological  evidence  for  deficits  com-
mon  among  childhood  ALL  survivors  have  impli-
cated white matter abnormalities, which may result 
from a disruption of the myelinization process occur-
ring during childhood [2].  Along with white matter 
hypodensity, MTX also causes leukoencephalopathy, 
multiple necrotic lesions in the periventricular white 
matter [13,44].  Behavioral symptoms correlated with 
this type of injury occur gradually over time, begin-
ning with decreased attentiveness and leading to in-
tellectual decline [45].  Impairment in attentional abil-
ities accounted for a significant amount of the vari-
ance  relating  to  reduced  volumes  of  nor-
mal-appearing white matter and IQ [46].  Moreover, 
cumulative (12 to 30) IT doses of MTX correlates pos-
itively with deficits observed in neuropsychological 
tests  of  IQ,  attention,  and  concentration  [47].    The 
identification  of  folate  pathway  genetic  polymor-
phisms that predict childhood cancer patients at-risk 
for developing attentional impairment following MTX 
treatment is underway [27]. 
In  general,  myelinization  appears  to  follow 
functional  maturation  across  brain  regions  [48].  
During childhood, one area of the brain undergoing a 
significant amount of myelinization is the frontal lobe 
[2].  Since myelinization in this area typically occurs 
later  in  development,  and  the  mature  frontal  lobe 
characteristically has a high volume of white matter, it 
may  be  more  vulnerable  to  damage  early  in  life.  
Volumetric reductions of the dorsolateral prefrontal 
cortices, along with the mammillary bodies and cau-
date nuclei, were examined in survivors three years 
post-treatment  who  had  received  IT  chemotherapy 
[49].  Despite no significant difference in global vol-
umetric brain size, a reduction was found in both the 
mammillary bodies and dorsolateral prefrontal corti-
ces.  The caudate nuclei, thought to develop earlier, 
were not significantly different in structure from con-
trols.    This  pattern  of  abnormality  corresponds  to 
noted deficits of memory, processing speed, distracti-
bility,  and  attention  in  childhood  ALL  survivors.  
Advanced  neuroimaging  techniques  that  allow  for 
more  precise  measurement  of  myelin  integrity  and 
degradation have been proposed for use in this pop-
ulation,  which  include  diffusion  tensor  imaging, 
quantitative  magnetization  transfer  imaging,  and 
quantitative  multiple  exponential  T2  measurements 
[42]. 
When studied in vitro, primary, non-cancer cells 
were more vulnerable to the toxic effects of cytara-
bine, BCNU, and cisplatin than cancer cells.  At a dose 
equivalent to a low-dose cancer treatment regimen, 60 
percent  of  oligodendrocytes  were  killed  within  24 
hours.  Similarly, at a dose equivalent to the lower end 
of a  high-dose  cancer  treatment  regimen,  nearly all 
oligodendrocytes were killed along with 50 percent of 
glial-restricted precursor cells [50].  Recent evidence 
supports that chemotherapeutic agents once thought 
unable  to  readily  cross  the  blood-brain  barrier,  in-
cluding doxorubicin, reduce neural cell proliferation 
in the dentate gyrus [51].  This mechanism has not yet 
been  evaluated  from  a  developmental  standpoint, 
which is important to consider since the blood-brain 
barrier of a child is still undergoing development and 
is  therefore  more  susceptible  to  chemothera-
py-induced CNS damage.    
A multitude of potential mechanisms underlying 
chemotherapy-induced  cognitive  deficits  have  been 
proposed,  although  not  specifically  in  relation  to 
childhood  cancer  survivors.    In  addition  to  white 
matter  damage  and  reduced  cell  proliferation  dis-
cussed  above,  proposed  additional  mechanisms  in-
clude increased oxidative stress, neuroinflammation, 
reduced blood flow, deregulation of the immune re-
sponse, and deficits in DNA-repair mechanisms [52,53 
for  extensive  reviews].    Examining  the  deleterious 
effects  of  chemotherapeutic  agents  and  correlating 
these effects with behavioral measures using neural 
cells, immature brains, and mature brains may pro-
vide valuable insight into the mechanisms underlying 
cognitive late effects in ALL survivors.      
The Benefits of Preclinical Rodent Models 
It is not feasible in a human patient population to 
conduct the type of empirically valid research study 
that is needed to answer the interrelated questions of 
which drugs, combinations, or doses are most at risk.  
Besides  the  ethical  implications  of  tampering  with 
treatment  regimens  that  have  proven  successful  in 
curing ALL, assessment of  improved cognitive out-
come would take years [54].  Additionally, it is diffi-
cult to separate drug effects from other factors, such 
as  physiological  consequences  of  cancer  or  patient 
depression [55].  Another option, that of retrospective Journal of Cancer 2011, 2 
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studies,  does  not  take  into  consideration  the  most 
recent  treatment  protocols  currently  in  use.    Fur-
thermore, this type of evaluation does not capture the 
developmental trajectory of the drug effects in ques-
tion, a particularly important factor related to child-
hood cancer survivors. 
An  alternative  method  to  study  disruption  of 
learning  processes  by  chemotherapeutic  agents  is 
through the use of preclinical models.  This type of 
paradigm allows drug effects to be addressed inde-
pendently of other possible contributing factors, and 
provides a rapid way to evaluate many drugs, both in 
terms of type and dosage.  With an average lifespan of 
about two years, rodents allow effects to be studied 
within a developmental framework as well.  Although 
many past studies involving chemotherapeutic agents 
and rodent models have involved drug administra-
tion of a single agent [56,57,58], rodent models make it 
possible to study drug combinations, thus providing a 
more accurate model of current protocols for child-
hood  cancer treatment.   Underlying mechanisms of 
chemotherapy-induced  neurotoxicity  such  as  de-
creased cell proliferation can only be studied using 
preclinical models.  Drugs that may prevent or allevi-
ate deleterious effects resulting from chemotherapeu-
tic  treatment  also  can  be  evaluated.    For  example, 
there  is  an  emerging  literature  examining 
methylphenidate as a possible treatment for cognitive 
late effects in the childhood cancer survivor popula-
tion  [59,60,61].    In  addition,  sex  differences  among 
drug effects can be examined in rodents, for there is 
some evidence to suggest that girls are more suscep-
tible to the neurotoxic effects of these agents [62].  
While  studies  examining  the  mechanisms  for 
chemotherapy-induced neurotoxicity in clinical stud-
ies  are  limited,  preclinical  models  in  adult  rodents 
have demonstrated that MTX and cytarabine manage 
to  cross  the  blood-brain  barrier  following  various 
routes of administration.  For instance, cell death and 
disruption  of  cell  division  occurs  in  vivo  following 
three systemic injections of cytarabine in mice [50].  A 
single  IV  dose  of  MTX  (37.5-300  mg/kg) 
dose-dependently reduces hippocampal cell prolifer-
ation in rats.  As the hippocampus is important for 
learning and memory, detrimental effects on cogni-
tive performance are likely to result if neurogenesis is 
disrupted.  This theory was supported by impairment 
following MTX treatment on the Morris water maze 
and  novel  object  recognition  tasks,  designed  to 
measure  spatial  and  working  memory,  respectively 
[63].  Furthermore, intracerebroventricular injections 
of MTX administered for three alternative days to rats 
resulted  in  lowered  concentrations  of  hippocampal 
brain amines.  These findings correlated with results 
from  a  conditioned  avoidance  task,  in  which  adult 
rats  treated  with  MTX  failed  to  learn  to  avoid  an 
aversive stimulus relative to controls [64].   
Rodent studies have also examined the impact of 
MTX on the younger, developing brain.  For example, 
MTX  (0.05  mg/kg  or  0.1  mg/kg,  i.p.)  administered 
during a critical period of brain development in rat 
pups leads to a reduced density of synapses in the 
CA3 field of the hippocampus [65].  Additionally, a 
model  of  MTX  encephalopathy  in  young  rats  was 
developed  by  administering  intraventricular  injec-
tions of MTX (1 or 2 mg/kg).  Five repeated doses 
produced  neuropathological  changes  similar  to  the 
damage seen in human patients [66].  However, no 
behavioral  measures  of  learning  were  included  in 
these studies.   
Preclinical models have been useful to investi-
gate  chemotherapy-induced  deficits  in  learning and 
memory  using  adult  models  of  breast  cancer  treat-
ment  within  a  variety  of  behavioral  assays 
[67,68,69,70].  These studies have important implica-
tions for other treatment protocols composed of mul-
tiple drug agents, such as ALL.  For instance, the use 
of  rodent  models  has  highlighted  the  possibility  of 
drug synergisms, i.e., drug combinations that have a 
greater  effect  than  either  drug  alone.    While  some 
regimens include drugs known to have specific syn-
ergistic  effects  that  aid  in  treating  the  cancer  itself, 
unwanted  side  effects,  including  cognitive  deficits, 
may  result  as  well  [67].    Strategies  for  attenuating 
chemotherapy-induced  cognitive  deficits  have  been 
examined in rodent models, including the use of an-
ti-depressants such as fluoxetine to block decreased 
cell  proliferation  following  treatment  with 
5-fluorouracil [71].  Fluoxetine also reverses the sup-
pression of neurogenesis produced by MTX in adult 
rodents [72].  Findings from these types of studies will 
help physicians make informed choices about treat-
ment  options  that  reduce  or  eliminate  chemothera-
py-induced  cognitive  deficits,  as  well  as  ways  in 
which  to  treat  these  impairments  should  they  arise 
[69].  
Rodent Models of Childhood Cancer Treat-
ment  
Studies using rodent models to elucidate the ef-
fects of childhood cancer treatment in young pups have 
been much more limited.  It is exceedingly important 
to study treatment in developing rodent brains, since 
neonatal damage has been found to have more severe 
long-term effects than identical damage in the mature 
adult rodent brain [73].  Although studies addressing 
the influence of MTX on the developing rodent brain 
exist, few include behavioral measures.  Additionally, Journal of Cancer 2011, 2 
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previous models of childhood treatment have gener-
ally  focused  on  an  acute  administration  of  a  single 
chemotherapeutic agent, typically MTX.  Of the stud-
ies  that  do  include  behavioral  measures  of  young 
pups, many entail assays that seem loosely tied and 
functionally  disconnected  from  the  actual  deficits 
displayed in human childhood cancer survivors.   
For  instance,  the  first  assessment  of  cancer 
treatment on developing brains used young rat pups 
at PND 17, an age selected because of developmental 
similarities  to  human  infants.    Treatment  included 
CRT alone (1,000 R), MTX alone (5 mg/kg, i.p.), or a 
combination of CRT and MTX.  Testing with a simul-
taneous discrimination task began when the rats were 
12-14  weeks  old.    Findings  demonstrated  that  only 
animals receiving a combination treatment were sig-
nificantly slower to reach criterion, compared to the 
rest of the groups [57].   
However, in contrast to ALL treatment protocols 
that include multiple phases of therapy, typically over 
the course of two years, this study tested a single dose 
of radiation and/or MTX.  According to the authors, 
this was done because the CNS of rats this age de-
velops at an exceedingly fast rate.  This limitation is 
shared  among  the  majority  of  studies  using  rodent 
models to investigate childhood cancer treatment in 
young pups.  In another study, rat pups 16-17 days 
old  were  treated  with  a  single  dose  of  MTX  (0.005 
mg/kg, i.p.).  At 12-14 weeks of age, animals were 
tested on conditioned emotional response and condi-
tioned  taste  aversion  tasks.    Animals  treated  with 
MTX acquired the delay conditioning at a slower rate.  
Rats also were tested on a conditioned taste aversion 
task, in which a previously highly palatable fluid was 
paired  with  illness.    MTX-treated  animals  failed  to 
display a taste aversion following the first trial, com-
pared to controls, but were equal to controls by the 
second  trial.    Given  the  above  results,  it  was  con-
cluded  that  neonatal  rats  administered  MTX  were 
slower to learn about environmental events [58].  In 
contrast, no impairments were found in 17-day-old rat 
pups treated with MTX (0.005 mg/kg, i.p.) in a similar 
conditioned taste aversion task, although a different 
strain of rats was studied.  Likewise, no impairment 
was found on a more complex Pavlovian conditioning 
task focusing on negative discrimination [56].  
 As already addressed, given the fact that child-
hood cancer regimens consist of an array of drugs, it is 
essential  to  examine  possible  interactions  that  may 
exist among them.  This issue was tackled by studying 
rats in nine different treatment combinations of MTX 
(2 or 4 mg/kg, i.p.), prednisolone (18 or 36 mg/kg, 
i.p.), and CRT (1000 cGy), treated at PND 17-18 [74].  
Steroids such as prednisolone are commonly included 
among the drugs used in ALL treatment, particularly 
in double and triple IT therapy, and there is evidence 
to  suggest  that  glucocorticoid  steroids  potentiate 
hippocampal damage caused by neurotoxins [75].  In 
this study, spontaneous behavior was measured for 
behavioral initiations, as well as time distribution and 
the sequence of behavioral acts.  Greater behavioral 
deficits  were  found as  the  treatment group  became 
more  complex.    Effects  also  were  dose  and 
sex-dependent,  with  females  displaying  altered  be-
havior at lower doses than males [74].  This is con-
sistent with clinical literature suggesting girls may be 
more susceptible to the aversive effects of these drugs 
[62].  While prednisolone antagonized MTX, thereby 
preventing behavioral alterations, at low doses, pred-
nisolone enhanced MTX and CRT-related deficits at 
high doses [74].   
In  addition  to  MTX,  cytarabine,  vincristine, 
doxorubicin, and L-asparaginase are commonly men-
tioned  in  clinical  studies  as  being  part  of  ALL 
chemotherapeutic  treatment,  but  information  per-
taining to the individual contributions of these agents 
to neurocognitive deficits is limited.  These types of 
evaluations  are  difficult  to  assess  through  clinical 
studies given that chemotherapeutic agents are often 
combined.    Therefore,  the  potential  involvement  of 
cytarabine,  vincristine,  doxorubicin,  and 
L-asparaginase cannot be dismissed for their contri-
butions to neurocognitive deficits.  Preclinical models 
have provided evidence of cognitive disruption fol-
lowing administration of these drugs, though research 
remains limited to adult rodents.  To date, cytarabine 
produced impairment in long-term spatial memory in 
rats 30 days post-training, but not 1 day post-training, 
on the Morris water maze [76].  Preclinical research 
involving  vincristine  has  largely  been  discussed  in 
relation  to  disrupted  sensory  processing,  including 
neuropathies  and  mechanical  sensitivity  [77],  but 
impairment  in  spatial  learning  as  measured  by  the 
Morris water maze has been noted at high doses [78].  
When administered alone, doxorubicin treatment led 
to impairment in inhibitory avoidance conditioning in 
rats,  but  not  on  a  passive  avoidance  task  in  mice 
[79,80].    In  combination  with  cyclophosphamide, 
doxorubicin produced impairment in contextual fear 
conditioning and passive avoidance learning in rats 
[81,82].  The link between L-asparaginase and cogni-
tion has not yet been examined, but is an important 
factor to consider for future research in this area.  The 
individual  effects  of  specific  corticosteroids,  com-
monly  used  in  combination  with  chemotherapeutic 
agents, are correlated with poor cognitive outcome as 
well.    For  example,  children  treated  with  dexame-
thasone may be at greater risk for neurocognitive late Journal of Cancer 2011, 2 
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effects, compared to children treated with prednisone 
[43].  
Future Directions 
Limitations  of  preclinical  models  of  childhood 
cancer treatment are obvious as several factors com-
plicate this type of research.  For instance, the early 
stages of rodent life are not yet definitively mapped 
out, although there are some guidelines about devel-
opmental milestones such as reflexes and locomotor 
behavior  [83],  and  age  equivalences  for  the  adoles-
cence  period  in  rodents  have  been  proposed  [84].  
Development of the blood-brain barrier and lack of 
certain  enzymes  at  early  stages  will  impact  how 
chemotherapeutic  agents  are  metabolized  by  the 
body, as well as how the brain is affected.  Decisions 
about dosage and route of administration also need to 
take  these  developmental  aspects  into  account  and 
limited  pharmacokinetic  and  pharmacodynamic 
models are available.  Additionally, the short lifespan 
of  rodents  means  that  progression  through  stages 
occurs at an accelerated rate.  This fact needs to be 
taken  into  consideration  when  choosing  behavioral 
assays, as well as when selecting the points along the 
lifespan that rodents are to be tested.  Nevertheless, 
use of adult rodents to study the effects of childhood 
cancer  does  not  take  into  consideration  treatment 
impact on a developing brain, as opposed to one that 
is already matured, and is therefore a less valid mod-
el. 
 Translational research entails basic science and 
clinical practice working together, with each inform-
ing the other.  Building a bridge between clinical and 
preclinical research would greatly improve the study 
of  chemotherapy-induced  cognitive  effects  of  child-
hood  cancer  treatment.    While  this  philosophy  has 
been applied to models of adult cancer, developmen-
tally focused accounts of childhood cancer treatment 
are limited.  Future preclinical research in this area 
should aim to provide a more accurate model of clin-
ical treatment through alterations in drug selection, 
treatment regimen, and behavioral measures.  Since 
MTX and cytarabine are commonly administered to-
gether during CNS prophylaxis in ALL treatment, it 
would  be  valuable  to  investigate  the  effects  of  this 
specific  combination  of  chemotherapeutic  agents.  
Preclinical models are ideal for parsing apart the in-
dividual  and  combined  effects  on  learning  and 
memory  of  lesser-studied  chemotherapeutic  agents 
used in ALL treatment, such as vincristine, doxorubi-
cin,  and  asparaginase.    Repeated  administration  of 
these  agents  can  be  examined  by  treating 
pre-weanling pups on multiple consecutive days early 
in development, rather than a single administration of 
treatment.  Rodents can be assessed during various 
stages of development, including adolescence (PND 
35) and adulthood (PND 60), to examine long-term 
effects of early neurotoxicity.   
In order to advance this area of research, appro-
priate  behavioral  assays  need  to  be  selected  that 
characterize  the  neurocognitive  deficits  experienced 
by  ALL  survivors.    Since  the  exact  mechanisms  of 
chemotherapy-induced cognitive impairment are not 
yet fully understood, a battery of preclinical assays of 
learning and memory should be studied, as sensitivity 
to  chemotherapy-induced  cognitive  deficits  differs 
among  tasks  in  models  of  adult  chemotherapeutic 
treatment [53].  Paradigms used in rodent models of 
childhood  cancer  treatment  are  much  more  limited 
and have typically focused on respondent condition-
ing.  Evaluating effects on instrumental conditioning 
will  provide  new  insight  into  the  type  of  learning 
processes  impaired  by  chemotherapeutic  treatment.  
Impairment  on  an  autoshaping-operant  procedure 
has  been  demonstrated  following  treatment  with 
MTX and 5-fluorouracil in adult mice [67], whereas no 
impairment was found on the five choice serial reac-
tion time task following treatment with paclitaxel [85].  
While both of these tasks measure instrumental con-
ditioning, the two procedures differ in terms of length 
of training.  This distinction would be interesting to 
examine within a developmental context, both in re-
gard to learning deficit as well as potential rehabilita-
tion.  Other cognitive assessments that have demon-
strated impairments following adult chemotherapeu-
tic treatment are useful for a developmentally-focused 
model of ALL, such as novel object recognition and 
the Morris water maze, which measure working and 
spatial memory, respectively [76,86].  It is particularly 
important to include tasks of sustained attention or 
vigilance,  as  these  deficits  are  pervasive  among 
childhood cancer survivors.  In addition to the five 
choice serial reaction time task previously discussed, 
the Go/No-go task also measures sustained attention 
through  reinforcer  delivery  being  contingent  upon 
responding in the presence of a cue [87].     
The  preclinical  research  discussed  here  all  in-
volved healthy rodents.  The validity of using healthy 
animals  to  study  chemotherapy-induced  neurotoxi-
city is supported by the finding that tumor presence 
does not potentiate a MTX-induced decrease of cell 
proliferation in the hippocampus [88].  A logical next 
step  will  be  to  investigate  learning  deficits  using  a 
model bearing an ALL-related cancer.  This will ena-
ble insight into the interaction between chemotherapy 
and the ALL cancer itself.  However, using immuno-
suppressed rodents may create a new set of challenges 
for  conducting  behavioral  testing,  particularly  if Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
299 
equipment is shared with rodents that do not have a 
compromised immune system.   
Conclusions 
In  summary,  with  survival  rate  for  childhood 
cancers on the rise, it is imperative that new research 
focuses on what happens after a child enters into re-
mission.  As has been recommended by the Children‘s 
Oncology Group, it is essential that children and their 
parents be informed of potential late effects [1].  Sur-
vivors  need  to  be  closely  monitored  by  healthcare 
workers and school personnel for emerging medical 
complications and/or academic difficulties, which, as 
noted in the current review, may not arise until sev-
eral years after treatment has ended.  Further guide-
lines relating to childhood cancer survivors are out-
lined  in  the  Long-Term  Follow-Up  Program  Resource 
Guide, available online from the Children‘s Oncology 
Group [1].  Attempts to create reliable and valid as-
sessment tools that can quickly identify at-risk survi-
vors are currently underway [89].  Additionally, as-
sessment of current multiple-phase treatment proto-
cols is needed to evaluate specific drug effects that 
may contribute to cognitive late effects.  These find-
ings  will  help  physicians  make  informed  choices 
about  treatment  options  that  reduce  or  eliminate 
chemotherapy-induced  neurocognitive  deficits,  in-
cluding attention and working memory, the presence 
of which have been supported by both behavioral and 
neurophysiological  evidence.    This  effort  will  be 
greatly  facilitated  through  converging  lines  of  re-
search  from  both  the  clinical  and  preclinical  litera-
tures.  Currently, a child‘s fight with cancer does not 
end with remission, but hopefully, with new efforts 
focusing on research in the area of late effects, one day 
it will. 
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